Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.35 |
| ▸ | TLR2 | O60603 | 6/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754240 | 0.97 | HTT (0.41) | HTTUSP2SPHK1TLR2CYP3A4 | |
| SCHEMBL25754235 | 0.95 | HTT (0.42) | HTTUSP2SPHK1TLR2CYP3A4 | |
| SCHEMBL25754237 | 0.92 | HTT (0.42) | HTTUSP2SPHK1TLR2CYP3A4 | |
| SCHEMBL25754247 | 0.85 | USP2 (0.51) | HTTUSP2SPHK1CYP3A4LPAR5 | |
| SCHEMBL25754242 | 0.83 | USP2 (0.49) | HTTUSP2SPHK1CYP3A4LPAR5 | |
| SCHEMBL25754493 | 0.82 | CYP3A4 (0.36) | HTTCYP3A4 | |
| SCHEMBL25754358 | 0.81 | CYP3A4 (0.33) | HTTSPHK1CYP3A4 | |
| SCHEMBL25754243 | 0.81 | USP2 (0.51) | HTTUSP2SPHK1CYP3A4LPAR5 | |
| SCHEMBL25754231 | 0.81 | USP2 (0.55) | HTTUSP2SPHK1CYP3A4LPAR5 | |
| SCHEMBL25754352 | 0.81 | CASP2 (0.36) | HTTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | HTT 916/4885USP2 51/4885SPHK1 4450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.